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Abstract
A characteristic feature of chronic inflammatory reactions is their persistence and predilection for
certain sites. The molecular basis for such tissue tropism (as, for example, seen with metastatic
spread) has until recently remained obscure, but recent studies have strongly implicated tissue-
resident, stromal cells, such as macrophages, endothelial cells and fibroblasts. These cell types
make attractive therapeutic targets as they help define the three-dimensional structure of tissues
and are key orchestrators of the inflammatory infiltrate. Most current anti-inflammatory therapies
target immune cells in an attempt to inhibit the production of pro-inflammatory mediators;
however, an equally important target is the active induction of anti-inflammatory mediators
involved in the resolution of inflammation. Recent work suggests that stromal cells are an
important source of these mediators. Targeting of multiple signals may be required to inhibit tissue
damage associated with inflammatory disease. Cells of the monocyte lineage are present as tissue-
resident cells and interact closely with other stromal populations. These cells form an ideal target
for modulation of the inflammatory environment as, in some cases, they appear to induce tissue
repair. Therapeutic manipulation of the stromal microenvironment has been particularly effective
in treating cancer and is likely to provide a novel method to achieve improved control of chronic
inflammatory disease.
Introduction
In the past ten years, a paradigm shift has occurred in the fields of inflammation and cancer
cell research. Haemopoietic cells (see Glossary) are no longer seen and analysed in isolation,
but need to be considered in the context of organ-specific stromal microenvironments. Such
environments are composed of tissue-specific cells, such as fibroblasts, endothelial cells and
resident macrophages, along with their highly specialised extracellular matrix (ECM)
components. Evidence exists that tissue stromal cells are able to determine the type and
duration of leucocyte infiltrates in an inflammatory response [1], whereas at the resolution
of such responses, stromal cells also contribute to the withdrawal of survival signals and
normalisation of chemokine gradients that allow infiltrating cells to undergo apoptosis or
leave through draining lymphatics. Subversion of these pathways results in a switch to
persistent inflammation, which remains remarkably stable [2•]. The relative lack of reagents
that target the dynamic leucocyte–stromal interactions may account for the failure of current
therapies to affect a permanent cure, as current treatments potentially miss many points
where leucocyte–stromal interactions occur. By contrast, more recent therapies, including
anti-tumour necrosis factor monoclonal antibodies and receptor Fc-fusion proteins, attempt
to inhibit the complex cytokine networks between stromal and haemopoietic cells. In
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targeting the stromal microenvironment, attempts are now being made to address the nature
of the switch from resolving to persistent disease that underlies many chronic inflammatory
diseases (Figure 1).
We consider a wider definition of stromal cells, to include tissue-resident cells
encompassing those of the monocyte/macrophage lineage. These highly specialised cells
form part of an organ-specific stromal network. As evidence of plasticity between
haemopoietic and mesenchymal lineages accumulates, it is clear that neither conventional
mesenchymal nor tissue-resident haemopoietic cells can be considered in isolation. We
consider the recent evidence for involvement of stromal cells and tissue macrophages in
rheumatoid arthritis (RA) and chronic liver disease, explore the relationship between
inflammation, wound healing and cancer, and discuss the pharmacological targets currently
or likely to be pursued in the next few years.
What is a stromal cell?
Two broad historical definitions of stromal cells exist. The first is that they are cells of
mesenchymal origin that are non-epithelium, non-endothelium and non-haematopoietic. The
second is that they are the cells resident within the tissue stroma and therefore include
fibroblasts, endothelial cells and tissue-resident leucocytes. Irrespective of these definitions,
stromal cells are responsible for defining the specialised architectures of organs and tissues
through the secretion of ECM components and characteristic cytokine and chemokine
combinations. Stromal cells have been defined in terms of their embryological origins and
lineage relationships, and are generally considered to be mesenchymal in origin. However,
the embryological mesenchyme, from which fibroblasts are derived, is not in itself a germ
layer (usually defined as ectoderm, endoderm and mesoderm), but is variably considered to
be either wholly composed of embryonic mesoderm or a combination of the mesoderm and
ectoderm or endoderm layers. For instance, in the head and neck, some mesenchyme is
derived from neural crest cells (and hence from ectoderm). Unfortunately the blood cell
lineages are also derived from the mesoderm, which means that haemopoietic stem cells are
also technically mesenchymal stem cells. Cell populations have now been identified that
appear to blur the distinction between haemopoietic and non-haemopoietic populations,
including the fibrocyte [3]. Moreover, other unexpected shifts in lineage have been reported,
including differentiation from neural stem cells into myeloid and lymphoid haemopoietic
lineages [4]. The standard approach to cellular classification is, therefore, becoming
increasingly awkward and means that some of the therapeutic effects of bone marrow
transplantation need to take these issues into account. The crucial importance of stromal
populations in the regulation of specialised tissue function and architecture is demonstrated
by the strong association of stromal cell defects with tumourigenesis [5,6].
Our inability to precisely define the prototype stromal cell, the fibroblast, using phenotypic
markers has significantly retarded progress in the field. Descriptions of different fibroblasts,
therefore, generally rely upon a combination of morphology, phenotypic markers (often
negative, ruling out other contaminants) and functional features, whereas
immunohistochemistry and in situ hybridisation often rely almost entirely upon
morphological features. Consequently, the discrete targeting of stromal cells such as
fibroblasts has been fraught with difficulty. However, transcriptional profiling is now
changing this situation; Chang et al. [7] have convincingly demonstrated that fibroblasts
from different sites can be consistently separated by their transcriptomes, which offers the
possibility of improved characterisation.
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Stromal cells and inflammation
Fibroblasts
The most abundant cells of the stroma are fibroblasts, which are responsible for the
synthesis and remodelling of EMCs. In addition, their ability to produce and respond to
growth factors allows reciprocal interactions with other stromal cell types and with adjacent
epithelial and endothelial structures. As a consequence, fibroblasts play a critical role during
tissue development and homeostasis and are often described as having a ‘sentinel’ or
‘landscaping’ function. Moreover, these functions contribute to the pathology of many
diseases either directly, for example by overproduction of matrix components during
fibrosis, and/or indirectly, for example by influencing the behaviour of neighbouring cell
types.
Rheumatoid arthritis synovial fibroblasts (RA SFbs) provide a convincing example of how
stromal cells contribute to the persistence of inflammation. RA SFbs are now known to be
direct effectors of tissue injury and remodelling. They display an imprinted phenotype that is
stable under in vitro culture conditions, and which extends to functionally important
outcomes, such as cartilage invasion, as demonstrated in severe combined immunodeficient
(SCID) mouse models [8]. RA SFb-mediated erosion of cartilage and bone determines
disease outcome for the majority of RA patients [9]. Furthermore, evidence suggests that,
through secretion of cytokines and chemokines, SFbs play a role in the persistence of
inflammation in the synovium through recruitment and retention of effector cells of the
immune system [10].
Type I interferons are produced by the expanded stromal population of SFbs and
macrophages, which results in a lack of proliferation but also a block of the apoptotic signals
that normally result in a coordinated wave of T lymphocyte death at the conclusion of an
inflammatory response [11-13]. Unexpectedly, CD45RO+ T lymphocytes were found to
express CXCR4 receptors at high levels in the rheumatoid synovium. The ligand for
CXCR4, CXCL12, is highly expressed on endothelial cells at the sites of T cell
accumulation [13-15]. In addition, stromal-cell-derived tumour growth factor-β (TGF-β) is
responsible for the upregulation of CXCR4 receptors on T cells in the synovium, and may
be responsible for the production of a new subset of interleukin (IL)-17-producing cells
called TH-17 that have been strongly implicated in immune-mediated inflammatory diseases
[16••]. Cross-talk between chemokine and cytokine networks may operate to reinforce the
retention of T cells by CXCL12, as locally raised IL-1 and tumour necrosis factor-α (TNFα)
levels cause synovial fibroblasts and macrophages to secrete IL-15, which upregulates
CXCR4 on T cells, and may thus also contribute to the retention of T lymphocytes [14].
There is, therefore, clear evidence in support of the hypothesis that aberrant expression of
constitutive chemokines by SFbs is responsible for retention of T cells within the RA
synovium. These studies have been supported by data on the targeting of CXCR4 in murine
models of arthritis where the CXCR4 antagonists AMD3100 and 4F-benzoyl-TN14003
ameliorated disease severity in DBA/1 (interferon-γ receptor deficient) mice and collagen-
induced arthritis (CIA), respectively [17,18]. It is possible that CXCR4 antagonists will be
of use in the therapy of RA provided that toxicity issues caused by stem cell mobilisation
from the bone marrow, which depend upon CXCL12/CXCR4 interactions, do not pose a
major problem.
The unique, imprinted phenotype of RA SFbs bears remarkable phenotypic similarities to
stromal cells of the bone marrow concerned with the recruitment and support of
haemopoietic cells [19]. Recent studies have suggested that the phenotype of RA SFb is
accounted for by accumulation of blood-borne stromal progenitor cells (mesenchymal
progenitor cells) [19]. Other possible sources of stromal cells in inflammatory diseases
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include epithelial to mesenchymal transition, a phenomenon observed in inflammatory
diseases of the kidney at sites of epithelial injury [20]. Targeting of such transdifferentiation
processes may prove useful in retarding fibrotic diseases such as systemic sclerosis [21].
Endothelial cells
Endothelial cells are responsible for vascular tone, haemostasis and the transport of cells and
soluble mediators throughout the body, with diverse phenotypes ranging from large arteries
to capillaries and lymphatic endothelium. Tissue injury results in release of lipid mediators,
endothelial upregulation of adhesion molecules, and production and release of chemokines,
such as CXCL8 (IL-8), which results in adherence and transmigration of leucocytes. Recent
advances have improved our understanding of the transcriptional diversity of endothelial
cells [22], and also of the interactions that occur between endothelial cells and associated
stromal cells, such as pericytes, macrophages and fibroblasts [23,24•]. Growth of
inflammatory or neoplastic tissue requires new blood vessel formation or angiogenesis to
occur. Angiogenesis itself requires the presence of new organ-specific vascular cells, a
network of associated supporting stromal cells (pericytes) and ECM, which are normally
responsible for tight control through factors such as vascular endothelial growth factor
(VEGF) and basic fibroblast growth factor (bFGF) [25]. Studies targeting VEGF are
compelling. They demonstrate that blockade of VEGF, its receptors or its downstream
signalling pathways is able to ameliorate disease in both ex vivo and in vivo models. This
suggests that VEGF activity is necessary for the persistence of inflammation in arthritis. A
VEGF receptor–Fc construct suppressed synovial endothelial proliferation in RA synovial
tissue explants [26]. In CIA models, anti-VEGF has been shown to reduce arthritis onset and
severity, whereas VEGF receptor Flt-1 blockade reduces synovial angiogenesis [27].
Antibodies to VEGF-R1 and a VEGF-R1 tyrosine kinase inhibitor in K/BxN murine arthritis
also led to amelioration of disease [28]. It is likely that targeting of angiogenesis will be a
therapeutic reality in the near future.
A recent breakthrough in the elucidation of trafficking pathways has been the development
of specific markers for lymphatic, as opposed to vascular, endothelium. Of these, the most
specific is LYVE-1: a hyaluronan receptor expressed exclusively on draining lymphatic
vessels [29]. Markers such as LYVE-1 now allow the potential targeting of lymphatic
vessels, which control trafficking out of inflammatory environments. In RA synovium,
deregulation of chemokine gradients occurs, which suggests that tissue expression of
constitutive chemokines plays a role in lymphocyte retention by subverting the normal CK
gradient (which causes egress through lymphatics) towards draining lymph nodes [30].
Monocytes as haemopoietic/stromal cell intermediates
Upon stimulation, monocytes differentiate into a wide variety of cells, including
macrophages, dendritic cells and osteoclasts [31,32]; however, emerging data suggest that
monocytes may be able to differentiate down a number of stromal cell lineages to produce
endothelial cells and fibroblasts [33]. The presence of such stromal plasticity in the
monocyte lineage may help to address the wider question of the haematopoietic origins of
stromal cells seen in inflammation and wound healing.
Fibrocytes are adherent cells with a spindle-shaped morphology arising from within the
CD14-positive (monocyte) fraction of peripheral blood, and they express major
histocompatability complex class II as well as type I collagen and other ECM molecules
[34]. They have been shown to rapidly enter sites of tissue injury [35] where they elaborate
collagen-based matrix and have been proposed to differentiate along fibroblast lineages
under the influence of cytokines, particularly TGF-β [3]. Fibrocytes have also been shown to
contribute to tissue remodelling in models of inflammatory lung disease [36]. In lung
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fibrosis models, the CXCL12–CXCR4 chemokine–receptor pair has been identified as
essential in the recruitment of fibrocytes because targeting of CXCR4 with monoclonal
antibodies was shown to ameliorate disease [37••].
Further research linking monocytes and tissue resident stromal cells involves CX3CR1 —
the receptor for the chemokine fractalkine. Peripheral blood monocytes can be split into two
populations depending on their expression of this receptor. The CX3CR1-low population
(‘inflammatory monocytes’) are recruited to inflammatory sites, whereas the CX3CR1-high
population (‘immune monocytes’) are recruited to tissues where they differentiate into
various resident cell populations, including Kupffer cells and Langerhans cells [38]. It may,
therefore, be possible to selectively target those cells that participate in persistent
inflammatory responses without impairing physiological immune function.
Selective depletion of stromal cell subsets
The proven therapeutic effects of antibodies that deplete specific subsets of cells in the
treatment of leukaemia and transplant rejection has provided a proof-of-concept that such
cell-depletion strategies can be very effective. Is it possible that persistent inflammation
could be ameliorated by targeted depletion of specific cell subpopulations, such as
monocytes, macrophages and fibroblasts? Data from models of hepatic fibrosis suggest that
resident populations of hepatic macrophages are able to modulate the processes of fibrotic
progression and subsequent liver recovery. Stellate cells (specialised liver fibroblasts) are
known to differentiate during the process of hepatic injury and fibrosis towards a pro-
fibrotic, secretory myofibroblast phenotype under the influence of cytokines such as TGF-
β1, of which hepatic macrophages are a potentially important source [39]. High expression
of tissue inhibitor of metalloproteinase-1 (TIMP-1) by stellate cells/myofibroblasts appears
to maintain their survival and inhibit degradation of matrix [40]. During recovery from
fibrosis, myofibroblasts undergo apoptosis accompanied by a fall in TIMP-1 expression and
degradation of scarring matrix [41]. Expression by macrophages of TNF-related apoptosis-
inducing ligand (TRAIL) by macrophages is one mechanism by which stellate cell apoptosis
has been proposed to occur [42]. Using a transgenic mouse model of fibrosis, which allowed
discrete depletion of macrophage lineage cells under the influence of diphtheria toxin,
Duffield et al. [43••] were able to demonstrate a fascinating divergence of macrophage
functional regulation of these processes. Depletion of macrophages during the progression
phase of fibrosis resulted in decreased scarring and fewer myofibroblasts; however, when
macrophages were depleted in the early phases of recovery, sustained accumulation of
scarring matrix occurred [43••] (Figure 2).
Divergence of macrophage phenotypes during opposing processes of injury and repair could
be due either to phenotypic switching of existing cells or to recruitment of new, functionally
different, cells: a question that has yet to be resolved [39]. However, although depletion of
fibroblast subsets remains a distant possibility, macrophage lineage tissue-resident cells may
be a viable target for depletion, allowing us to modify interactions between different stromal
cell subpopulations with therapeutic benefit.
Relationship between inflammation and repair: lessons from targeting
stromal cells in cancer
Wound healing, chronic persistent inflammation and cancer exhibit significant parallels.
They are all associated with deposition of new ECM and expansion of adjacent stromal
cells, including fibroblasts, smooth muscle cells and endothelial cells. Furthermore, many
authors have drawn parallels between tumourigenesis and wound healing: classically
describing tumours as wounds that fail to heal [44]. Chang et al. [45••] recently
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demonstrated that the transcriptional response programme of fibroblasts to serum, as seen in
wound healing, was also seen in tumour and associated stromal cells. The presence of its
signature in tumour samples was found to be predictive of metastasis and death in common
cancers. Much has been learnt about the communication between networks of stromal cells
within tissues — pathological alterations of which are crucial to the process of
tumourigenesis. Parrinello et al. [46] found that senescent fibroblasts were able to disrupt the
normal branching morphogenesis of breast epithelial cells by secreted factors, including
matrix metalloproteinases (MMPs) and epithelial growth factors. When cultured with
premalignant cells, this disruption resulted in loss of differentiation representing malignant
transformation. This bystander effect of senescence, itself a means of controlling potentially
neoplastic cells, appears paradoxical and has been suggested to account for the age-related
incidence of epithelial cancers. It is also an indication that simply inducing apoptosis or
senescence of putative inflammatory stromal cells may have adverse effects. By contrast,
most researchers describe an activated, secretory phenotype of tumour-associated
fibroblastic cells [5,6]. A number of important cytokines and growth factors has been
described that contribute to neoplastic transformation of epithelial cells by activated tumour-
associated fibroblasts: these include hepatocyte growth factor, TGF-β, MMPs and FGFs.
Crucially, in contrast to senescent fibroblastic cells, tumour-activated fibroblasts appear able
to transform normal, in addition to pre-malignant, epithelial cells [6]. Blockade of both
TGF-β and the hepatocyte growth factor receptor c-Met has been effective in inhibiting both
the development and the metastasis of neoplasms in animal models [47,48]. Conversely, and
confirming the essential organ-like nature of the tumour as both ‘cancer cells’ and their
surrounding stroma, human breast cancer xenografts are unable to implant successfully into
mice unless accompanied by human tumour-derived fibroblasts [49••].
Release of growth factors, such as TGF-β, bFGF, VEGF, platelet-derived growth factor,
MMPs and proteolytic enzymes, by tumour cells in turn modifies the tumour stroma and its
cells to become angiogenic and pro-migratory [5]. The angiogenic properties of tumours are
therefore a cooperative product of tumour cells, tumour-associated stromal cells and
angiogenic factors released by proteolysis of the ECM. Studies using a skin surface model of
tumourigenesis indicated that expression of VEGF was ubiquitous amongst benign and
malignant tumours; however, it was the upregulation by stromal endothelial cells of VEGF
receptors that led to tumour invasion, with blockade of such receptors halting tumour
progression [50]. The concept of tumour stroma ‘normal-isation’ has now become an
accepted aspect of new oncology therapies. Clinical studies of angiogenesis inhibitors and
antibodies against ECM components, such as tenascin, have been favourable, and inhibitors
of MMPs, overexpression of TIMPs and blockade of integrin signalling have all shown
promise in pre-clinical trials [5]. Results of studies examining the interactions between
endothelial cells and their associated pericytes underline the importance of targeting the
stroma as a whole. Bergers et al. [51] have shown that endothelial cells release PDGF,
which induces VEGF production from pericytes leading to bidirectional conversations
between the two cell types. Interrupting these conversations by using PDGF inhibitors
proved to be more effective therapy than using VEGF inhibitors alone. Interestingly,
although VEGF inhibitors lost their inhibitory effect in later stage tumours, targeting of the
pericytes helped even late stage tumours to regress. The authors have subsequently shown
that pericyte precursors are partly recruited from the bone marrow to tumour perivascular
sites [52•]. Recent evidence using breast carcinoma models have shown that tumour-
associated fibroblasts secrete CXCL12, which results in increased promotion of carcinoma
cell growth compared with control fibroblasts, but also to recruitment of endothelial cell
precursors [53••].
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Conclusions
Stromal cells, such as endothelium, fibroblasts and tissue-resident macrophages, have great
potential as therapeutic targets. They are responsible for orchestrating and maintaining the
presence of inflammatory infiltrates. Classical approaches using antibody blockade of
cytokines such as TNFα have been spectacularly successful. The targeted depletion of
tissue-resident cells using cell depletion opens an alternative and exciting new avenue.
Furthermore, experience in the field of cancer medicine has highlighted approaches using
unconventional agents, such as protease inhibitors and matrix components, and emphasised
the necessity to understand the conversations occurring between different stromal cell
populations. Lastly, naturally occurring stromally derived factors that aid the resolution of
inflammation have great immediate potential for therapeutic use and are likely to become
important targets for further research.
Glossary
Angiogenesis the growth of new blood vessels
Haemopoietic cells those cells considered developmentally to arise from
haemopoietic stem cells, principally the erythroid, lymphoid and
myeloid lineages
Extracellular matrix the complex network of polysaccharides and proteins secreted by
cells, forming a structural component of tissues that also
influences their development and physiology
Tissue-resident cells cells characteristic of, and remaining within, a given tissue
regardless of origin. Includes fibroblasts, endothelial cells,
pericytes and tissue-specific macrophages
Tumourigenesis the process by which tumours are formed
References and recommended reading
Papers of particular interest, published within the annual period of review, have been
highlighted as:
• of special interest
•• of outstanding interest
1. Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M. Fibroblasts regulate the
switch from acute resolving to chronic persistent inflammation. Trends Immunol. 2001; 22:199–
204. [PubMed: 11274925]
2•. Parsonage G, Filer AD, Haworth O, Nash GB, Rainger GE, Salmon M, Buckley CD. A stromal
address code defined by fibroblasts. Trends Immunol. 2005; 26:150–156. [PubMed: 15745857]
This review summarises recent findings showing that fibroblasts help define a tissue-specific area
postcode, similar to the vascular area postcodes controlling leucocyte egress from the blood into
tissue.
3. Metz CN. Fibrocytes: a unique cell population implicated in wound healing. Cell Mol Life Sci.
2003; 60:1342–1350. [PubMed: 12943223]
4. Bjornson CR, Rietze RL, Reynolds BA, Magli MC, Vescovi AL. Turning brain into blood: a
hematopoietic fate adopted by adult neural stem cells in vivo. Science. 1999; 283:534–537.
[PubMed: 9915700]
5. Mueller MM, Fusenig NE. Friends or foes — bipolar effects of the tumour stroma in cancer. Nat
Rev Cancer. 2004; 4:839–849. [PubMed: 15516957]
Filer et al. Page 7
Curr Opin Pharmacol. Author manuscript; available in PMC 2011 June 21.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
6. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression.
Nature. 2004; 432:332–337. [PubMed: 15549095]
7. Chang HY, Chi JT, Dudoit S, Bondre C, van de RM, Botstein D, Brown PO. Diversity, topographic
differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci USA. 2002;
99:12877–12882. [PubMed: 12297622]
8. Muller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE, Gay S. Synovial
fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when
engrafted into SCID mice. Am J Pathol. 1996; 149:1607–1615. [PubMed: 8909250]
9. Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or
transformed aggressors? Arthritis Rheum. 1996; 39:1781–1790. [PubMed: 8912499]
10. Ritchlin C. Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis.
Arthritis Res. 2000; 2:356–360. [PubMed: 11094448]
11. Salmon M, Scheel-Toellner D, Huissoon AP, Pilling D, Shamsadeen N, Hyde H, D’Angeac AD,
Bacon PA, Emery P, Akbar AN. Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin
Invest. 1997; 99:439–446. [PubMed: 9022077]
12. Pilling D, Akbar AN, Girdlestone J, Orteu CH, Borthwick NJ, Amft N, Scheel-Toellner D,
Buckley CD, Salmon M. Interferon-beta mediates stromal cell rescue of T cells from apoptosis.
Eur J Immunol. 1999; 29:1041–1050. [PubMed: 10092109]
13. Buckley CD, Amft N, Bradfield PF, Pilling D, Ross E, Arenzana-Seisdedos F, Amara A, Curnow
SJ, Lord JM, Scheel-Toellner D, Salmon M. Persistent induction of the chemokine receptor
CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the
rheumatoid synovium. J Immunol. 2000; 165:3423–3429. [PubMed: 10975862]
14. Nanki T, Hayashida K, El Gabalawy HS, Suson S, Shi K, Girschick HJ, Yavuz S, Lipsky PE.
Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+
T cell accumulation in rheumatoid arthritis synovium. J Immunol. 2000; 165:6590–6598.
[PubMed: 11086103]
15. Pablos JL, Santiago B, Galindo M, Torres C, Brehmer MT, Blanco FJ, Garcia-Lazaro FJ.
Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in
rheumatoid arthritis. J Immunol. 2003; 170:2147–2152. [PubMed: 12574387]
16••. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT.
Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper
type 1 and 2 lineages. Nat Immunol. 2005; 6:1123–1132. [PubMed: 16200070] A recent finding
that a new subset of T-helper cells (termed ThIL-17 because of their unique ability to produce
Il-17), which have been implicated in the development of chronic immune-mediated
inflammatory disease, can be generated when the levels of classical Th1 and Th2 cytokines are
low in tissues.
17. Matthys P, Hatse S, Vermeire K, Wuyts A, Bridger G, Henson GW, De Clercq E, Billiau A, Schols
D. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine
receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice.
J Immunol. 2001; 167:4686–4692. [PubMed: 11591799]
18. Tamamura H, Fujisawa M, Hiramatsu K, Mizumoto M, Nakashima H, Yamamoto N, Otaka A,
Fujii N. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis
agent. FEBS Lett. 2004; 569:99–104. [PubMed: 15225616]
19. Edwards JC. Fibroblast biology. Development and differentiation of synovial fibroblasts in
arthritis. Arthritis Res. 2000; 2:344–347. [PubMed: 11094446]
20. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. Evidence that fibroblasts derive
from epithelium during tissue fibrosis. J Clin Invest. 2002; 110:341–350. [PubMed: 12163453]
21. Postlethwaite AE, Shigemitsu H, Kanangat S. Cellular origins of fibroblasts: possible implications
for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol. 2004; 16:733–738. [PubMed:
15577612]
22. Chi JT, Chang HY, Haraldsen G, Jahnsen FL, Troyanskaya OG, Chang DS, Wang Z, Rockson SG,
van de RM, Botstein D, Brown PO. Endothelial cell diversity revealed by global expression
profiling. Proc Natl Acad Sci USA. 2003; 100:10623–10628. [PubMed: 12963823]
Filer et al. Page 8
Curr Opin Pharmacol. Author manuscript; available in PMC 2011 June 21.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
23. Nash GB, Buckley CD, Ed RG. The local physicochemical environment conditions the
proinflammatory response of endothelial cells and thus modulates leukocyte recruitment. FEBS
Lett. 2004; 569:13–17. [PubMed: 15225601]
24•. Lally F, Smith E, Filer A, Stone MA, Shaw JS, Nash GB, Buckley CD, Ed RG. A novel
mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthritis
Rheum. 2005; 52:3460–3469. [PubMed: 16255036] A novel three-cell co-culture model that
recapitulates many of the in vivo dynamic interaction between leucocytes, endothelial cells and
stromal cells.
25. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003; 3:401–
410. [PubMed: 12778130]
26. Sekimoto T, Hamada K, Oike Y, Matsuoka T, Matsumoto M, Chosa E, Suda T, Tajima N,
Yamamura K. Effect of direct angiogenesis inhibition in rheumatoid arthritis using a soluble
vascular endothelial growth factor receptor 1 chimeric protein. J Rheumatol. 2002; 29:240–245.
[PubMed: 11838840]
27. Miotla J, Maciewicz R, Kendrew J, Feldmann M, Paleolog E. Treatment with soluble VEGF
receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest. 2000; 80:1195–
1205. [PubMed: 10950110]
28. De Bandt M, Ben Mahdi MH, Ollivier V, Grossin M, Dupuis M, Gaudry M, Bohlen P, Lipson KE,
Rice A, Wu Y, et al. Blockade of vascular endothelial growth factor receptor I (VEGF-RI), but not
VEGF-RII, suppresses joint destruction in the K/BxN model of rheumatoid arthritis. J Immunol.
2003; 171:4853–4859. [PubMed: 14568965]
29. Jackson DG. The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1.
Trends Cardiovasc Med. 2003; 13:1–7. [PubMed: 12554094]
30. Burman A, Haworth O, Hardie DL, Amft EN, Siewert C, Jackson DG, Salmon M, Buckley CD. A
chemokine-dependent stromal induction mechanism for aberrant lymphocyte accumulation and
compromised lymphatic return in rheumatoid arthritis. J Immunol. 2005; 174:1693–1700.
[PubMed: 15661933]
31. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes
from dendritic cells to macrophages. Nat Immunol. 2000; 1:510–514. [PubMed: 11101873]
32. Danks L, Sabokbar A, Gundle R, Athanasou NA. Synovial macrophage-osteoclast differentiation
in inflammatory arthritis. Ann Rheum Dis. 2002; 61:916–921. [PubMed: 12228163]
33. Kuwana M, Okazaki Y, Kodama H, Izumi K, Yasuoka H, Ogawa Y, Kawakami Y, Ikeda Y.
Human circulating CD14+ monocytes asa source of progenitors that exhibit mesenchymal cell
differentiation. J Leukoc Biol. 2003; 74:833–845. [PubMed: 12960274]
34. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN. Peripheral blood fibrocytes: differentiation
pathway and migration to wound sites. J Immunol. 2001; 166:7556–7562. [PubMed: 11390511]
35. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new
leukocyte subpopulation that mediates tissue repair. Mol Med. 1994; 1:71–81. [PubMed: 8790603]
36. Schmidt M, Sun G, Stacey MA, Mori L, Mattoli S. Identification of circulating fibrocytes as
precursors of bronchial myofibroblasts in asthma. J Immunol. 2003; 171:380–389. [PubMed:
12817021]
37••. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP,
Strieter RM. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate
fibrosis. J Clin Invest. 2004; 114:438–446. [PubMed: 15286810] This paper demonstrates not
only a crucial mechanism of fibrocyte recruitment in vivo, but also a pathological role in a
murine model of pulmonary fibrosis.
38. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct
migratory properties. Immunity. 2003; 19:71–82. [PubMed: 12871640]
39. Friedman SL. Mac the knife? Macrophages — the double-edged sword of hepatic fibrosis. J Clin
Invest. 2005; 115:29–32. [PubMed: 15630440]
40. Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJ, Benyon C, Iredale JP. Inhibition
of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is
mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver
fibrosis. J Biol Chem. 2002; 277:11069–11076. [PubMed: 11796725]
Filer et al. Page 9
Curr Opin Pharmacol. Author manuscript; available in PMC 2011 June 21.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
41. Parsons CJ, Bradford BU, Pan CQ, Cheung E, Schauer M, Knorr A, Krebs B, Kraft S, Zahn S,
Brocks B, et al. Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on
established liver fibrosis in rats. Hepatology. 2004; 40:1106–1115. [PubMed: 15389776]
42. Fischer R, Cariers A, Reinehr R, Haussinger D. Caspase 9-dependent killing of hepatic stellate
cells by activated kupffer cells. Gastroenterology. 2002; 123:845–861. [PubMed: 12198711]
43••. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, Wu S, Lang R,
Iredale JP. Selective depletion of macrophages reveals distinct, opposing roles during liver injury
and repair. J Clin Invest. 2005; 115:56–65. [PubMed: 15630444] A seminal study that
conclusively demonstrates that the timing of mono-cyte/macrophage deletion during liver fibrosis
determines whether fibro-sis persists or resolves. Deletion of macrophages during the early phase
leads to less fibrosis; during the later phases it leads to enhanced fibrosis.
44. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and
wound healing. N Engl J Med. 1986; 315:1650–1659. [PubMed: 3537791]
45••. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, Rijn MM,
Botstein D, Brown PO. Gene expression signature of fibroblast serum response predicts human
cancer progression: similarities between tumors and wounds. PLoS Biol. 2004; 2:E7. [PubMed:
14737219] The expression of a core set of serum response genes (i.e. genes that are upregulated
when fibroblasts are exposed to serum) in breast cancer predicts clinical outcome.
46. Parrinello S, Coppe JP, Krtolica A, Campisi J. Stromal-epithelial interactions in aging and cancer:
senescent fibroblasts alter epithelial cell differentiation. J Cell Sci. 2005; 118:485–496. [PubMed:
15657080]
47. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, Comoglio PM. Targeting the
tumor and its microenvironment by a dual-function decoy met receptor. Cancer Cell. 2004; 6:61–
73. [PubMed: 15261142]
48. Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J, Patel SC, Khozin S, Liu
ZY, Green J, et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against
metastasis without adverse side effects. J Clin Invest. 2002; 109:1607–1615. [PubMed: 12070308]
49••. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, Richardson A, Weinberg
RA. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc
Natl Acad Sci USA. 2004; 101:4966–4971. [PubMed: 15051869] A critical role for cancer
stromal cells in ensuring efficient engraftment of human breast cancer xenografts.
50. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE. Halting angiogenesis suppresses
carcinoma cell invasion. Nat Med. 1997; 3:1222–1227. [PubMed: 9359696]
51. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes
and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003;
111:1287–1295. [PubMed: 12727920]
52•. Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G. PDGFRbeta+ perivascular progenitor cells in
tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol. 2005; 7:870–879.
[PubMed: 16113679] This paper shows that pericyte survival and development is necessary for
efficient angiogenesis and that targeting both endothelial cells and pericytes leads to better anti-
tumour effects.
53••. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ,
Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas
promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;
121:335–348. [PubMed: 15882617] An elegant demonstration that stromal fibroblasts regulate
not only the site to which breast cancers metastasise but also the survival of metas-tasic cells
within those niches.
Filer et al. Page 10
Curr Opin Pharmacol. Author manuscript; available in PMC 2011 June 21.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 1.
Leukocyte–stromal interactions in chronic inflammatory disease. The molecular basis by
which leukocytes leave the circulation and migrate across endothelium has been well
studied; stromal and lymphatic trafficking remain less well understood. Leukocytes captured
by selectin/ligand interactions roll, sampling the presence of chemokines and other
activation markers on the endothelium and associated matrix proteins. Infiltrating cells
undergo firm adhesion then migrate through the endothelial layer following chemokine
gradients into the tissue stroma. Possible therapeutic targets here include inhibition of
angiogenesis using VEGF blockade, and blockade of specific chemokines and their
receptors including CXCL12/CXCR4. Alternatively, depletion of precursor cell populations
such as fibrocytes and endothelial precursors offers a means to control stromally mediated
inflammation and angiogenesis. Within the stroma, some cells are destined to die, such as
neutrophils. Others such as monocytes can differentiate into cells destined to die, such as
macrophages; others might proliferate. Potential targets within the stroma include deletion
of specific monocyte/macrophage populations with a pathological role, as suggested by
work in models of liver fibrosis (see text). Blockade of novel cytokines and chemokines, and
also of stromal/leukocyte cell-mediated interactions via molecules such as CD40, have
immediate therapeutic potential. Also potentially important is blockade of the
transdifferentiation of tissue resident cells such as monocytes into pathogically important
macrophage populations, or their accelerated apoptosis. Those cells destined to recirculate
must follow other chemokine gradients towards the lymphatic endothelium and exit from the
tissue towards draining lymph nodes. The endothelium regulates entry; the stroma regulates
proliferation, survival and differentiation; and the lymphatics regulate exit.
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Figure 2.
Divergence of macrophage function in fibrotic liver disease. During fibrosis progression
(rising solid line on graph), TGF-β1 is a potential macrophage-derived stimulator of stellate
cell activation. Depletion of macrophages during this phase results in decreased scarring and
fewer myofibroblasts, with decreased inflammation (small red arrow). During fibrosis
regression (falling solid line on graph), stellate cell apoptosis can occur under the influence
of macrophage-derived TRAIL. Depletion of macrophages early during fibrosis regression
results in sustained inflammation and accumulation of scarring matrix (large red arrow).
Hepatic macrophages thus have divergent effects on liver stellate cell activation in models of
fibrosis.
Filer et al. Page 12
Curr Opin Pharmacol. Author manuscript; available in PMC 2011 June 21.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
